One of the biggest challenges facing clinical trial sponsors and investigational sites centers on the efficient identification, recruitment and ongoing retention of sufficient numbers of…
A study from the Winship Cancer Institute of Emory University (Winship) has the potential to change how patients whose prostate cancer recurs after prostatectomy are…
Clinical Laserthermia Systems (publ) and Otto-von-Guericke-University Magdeburg, Medical faculty are entering into an agreement regarding an Investigator Initiated Trial (IIT) targeting MRI-Ultrasound fusion guided focal laser ablation treatment…
China’s Hinova Pharmaceuticals closed nearly $146 million in a series C round investment to support multicenter clinical trials and the commercialization of their leading drug…
Piedmont Healthcare is participating in two clinical research trials to study treatments for prostate cancer. One study examines the effects of stereotactic body radiation therapy…
A privately-held Seattle-based biotechnology company secured $1.44 million on the second of a competitive Small Business Innovation Research (SBIR) Phase IIB grant from the National…
University of South Australia researchers demonstrate that a new formulation of a prostate cancer treatment known as abiraterone acetate (Zytiga) could significantly transform the quality…
TrialSite News recently had the honor of interviewing Graham Kelly, a brilliant scientist, researcher, and Executive Chairman and CEO of Australia’s Noxopharm. Dr. Kelly established…
An elite scientific team developing new CAR T-cell gene therapy treatment for advanced metastatic prostate cancer at Abramson Cancer Center of the University of Pennsylvania…
Researchers from the Sidney Kimmel Cancer Center—Jefferson Health, Rutgers Cancer Institute and others are suggesting that among high-risk prostate cancer patients (e.g. those with high…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
